Lazard Healthcare Acquisition I registered with the SEC to offer 25 million units, each consisting of one Class A ordinary share and one-fifth of one redeemable warrant, with whole warrants exercisable at $11.50.
The new SPAC plans to target the biotechnology, medical technology, life science tools and diagnostics, healthcare information technology and technology-enabled healthcare services subsectors.
Lazard Healthcare is led by Executrive Chairman and Director Alexander Stern, president of Lazard Ltd and Lazard Group since June 2019 and managing director of Lazard since 2002.
The SPAC intends to apply for a listing on the Nasdaq under LHCAU. Read more.
